Global accounting and consulting firm Deloitte released its 2025 Technology Fast 500 list, which ranks the fastest-growing technology and life sciences companies across North America. The 31st annual list featured 31 companies from Boston. Last year’s list featured 34 companies.
Featured companies were selected based on their fiscal year revenue growth between 2021 and 2024 and ranked according to their percentage growth rate. Overall, this year’s ranking included Boston companies that achieved revenue growth ranging from 128 to 4,026 percent over those three years. Various technology, media, telecommunications, life sciences, fintech and energy tech companies are represented on the list.
“Our region’s technology sector has an ability to adapt in times of entrepreneurial challenge and emerge stronger. There is a foundation here built over centuries that provides a strong ecosystem for the next generation of industry leaders. We’re proud to recognize the growth of the companies from our area on this year’s Deloitte Technology Fast 500 list,” said Denise Diehl, audit and assurance managing director at Deloitte & Touche and Deloitte’s New England emerging growth company leader, in a statement.
Below are more details on the top five Boston-based tech companies included in this year’s Deloitte ranking. Make sure to check out the full list as well.
Top Boston Tech Companies on Deloitte’s 2025 Technology Fast 500
- Rhythm Pharmaceuticals
- Uwill
- Ardelyx
- Genetix Biotherapeutics
- Lumafield
Ranked #31, 4,026% Growth
Rhythm Pharmaceuticals is a biopharma company developing precision medicines that address the root cause of rare neuroendocrine diseases. Its lead medicine IMCIVREE is designed to treat severe obesity caused by an impairment in the MC4R pathway. The publicly traded company has a team of more than 250 employees across North America and Europe.
Ranked #32, 4,016% Growth
Uwill is a mental healthcare company offering teletherapy, crisis conversation and wellness programming services. Originally founded as an assistive tool for campus counseling centers, Uwill has expanded beyond the higher education market, and its platform now serves over 40 million people across all 50 states.
Ranked #37, 3,204% Growth
Ardelyx’s platform facilitates the discovery, development and commercialization of medicines. Through its drug discovery model, the company has identified biological mechanisms that enable it to create medicine intended to address unmet needs and improve patient outcomes. Ardelyx is currently running clinical trials for a treatment for irritable bowel syndrome in pediatric patients.
Ranked #53, 2,189% Growth
Genetix Biotherapeutics, recently rebranded from bluebird bio, develops genetic therapies that treat the underlying causes of sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy. Its therapies, Lyfgenia, Zenteglo and Skysona, are administered only once and have undergone decades of research and clinical experience.
Ranked #54, 2,155% Growth
Lumafield, a company specializing in 3D x-ray technology, allows engineers and manufacturers to capture an object’s internal and external structure in three dimensions. Its solutions help customers in sectors like aerospace and defense, agriculture, athletic equipment, automotive, medical devices and more avoid destructive testing, prototyping and potential recalls.
